BioSpace News Archive

Dermavant Sciences announced the completion of patient enrollment in the company’s PSOARING 1 and PSOARING 2 clinical trials of tapinarof, a potential first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent, in adult patients diagnosed with plaque psoriasis.

Siemens Healthineers announced the availability of its molecular Fast Track Diagnostics SARS-CoV-2 Assay test kit used to aid in the diagnosis of infection by the SARS-CoV-2 virus that causes the COVID-19 disease.

IVERIC bio, Inc. reported that on April 1, 2020, the Company granted newly hired employees equity-based awards.

Noxopharm, a clinical-stage Australian oncology drug development company, has identified a clinical trial opportunity that could help reduce the mortality rate of COVID-19.

Gained Rights to Product Candidate, CZN001 (renamed HZN-825), a Potential Treatment for Diffuse Cutaneous Systemic Sclerosis; a Rare Rheumatic Disease with No FDA-Approved Treatment

-- New results demonstrate P. gingivalis’ ability to infect neurons and cause characteristic Alzheimer’s pathology

Seattle Genetics, Inc. (Nasdaq:SGEN) today provided an update on the phase 1b/2 multicohort EV-103 trial (also known as KEYNOTE-869) of PADCEV TM (enfortumab vedotin-ejfv) in combination with anti-PD-1 therapy pembrolizumab for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting. Based on recent dis

Eyenuk, Inc., a global artificial intelligence medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced that it completed the first quarter of 2020 with encouraging business results.

Applied DNA and Takis Biotech Expand COVID-19 Vaccine Development Program to Include 5 th Candidate - Linear DNA Production for All Candidates Scheduled to Be Completed and Preclinical Animal Testing Expected to Commence This Month -

La Jolla Pharmaceutical Company today announced that it is providing GIAPREZA™ (angiotensin II) for named patient emergency use in patients with septic shock due to COVID-19 at Guy’s and St Thomas’ NHS Foundation Trust in London, United Kingdom. GIAPREZA is being made ava